Sign in

    Jake [on for Chase Knickerbocker]

    Senior Equity Research Analyst at Craig-Hallum

    Chase Knickerbocker is a Senior Equity Research Analyst at Craig-Hallum Capital Group, focused on specialty pharmaceuticals, biotech, and healthcare companies such as scPharmaceuticals and Xtant Medical Holdings. He is recognized for his rigorous research methodology and is actively tracked by major investment platforms like TipRanks for his stock recommendations, which include buy ratings on leading small and mid-cap firms across the life sciences sector. Knickerbocker's career has been built within Craig-Hallum, where he has steadily advanced to his current senior position, and he is noted for consistently providing data-driven insights to institutional investors. He holds necessary professional credentials as a registered securities analyst, maintaining compliance with FINRA standards.

    Jake [on for Chase Knickerbocker]'s questions to Xtant Medical Holdings (XTNT) leadership

    Jake [on for Chase Knickerbocker]'s questions to Xtant Medical Holdings (XTNT) leadership • Q3 2024

    Question

    Inquired about the expected contribution from the Viable Bone Matrix (VBM) product in Q4 and 2025, the mix between white-label and distributor sales, and the primary drivers for profitability next year.

    Answer

    The company expects the VBM contribution in Q4 to be primarily from the white-label side, with the distributor side picking up in Q1 2025 as existing inventories are depleted. Profitability improvements in 2025 are expected from both gross margin expansion (3-4 points) and improved operating leverage, driven by a better product mix and cost controls.

    Ask Fintool Equity Research AI